BCL2 and acute myeloid leukemia: The BH3 mimetic venetoclax (ABT-199) is a potent Bcl-2 selective inhibitor (11) approved for the use in chemotherapy-unfit patients with chronic lymphocytic leukemia (CLL) and older acute myeloid leukemia (AML), able to induce rapid apoptosis in blood-derived leukemic cells in vitro and showing promising results in the clinic (12–14).